EUVIMEDEUVIMED entdecken
Crossref

Targeting the Glutamatergic System in Bipolar Disorder - A Review of Pharmacological Approaches

Margarida Coutinho, Fernando Moreira, Marlene Santos

Proceedings of Research and Practice in Allied and Environmental Health · 16.05.2026

DOI: 10.26537/prpaeh.v4i2.7367 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of Research and Practice in Allied and Environmental Health, erschienen am 16.05.2026. Verfasst von Margarida Coutinho und 2 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bipolar disorder is a chronic mental disorder characterized by episodes of mania/hypomania and depression, with significant functional impairment and high global prevalence1,2. Although mood stabilizers and antipsychotics remain the standard treatment, their effectiveness is often limited by adverse effects and poor adherence3,4. Additionally, several conventional mood stabilizers exhibit a delayed onset of action, requiring up to three weeks, which reduces their usefulness in acute episodes. Therefore, glutamatergic agents, such as ketamine, have emerged as promising alternatives due to their rapid antidepressant effects and neuroprotective mechanisms5,6.

Objectives

This study aimed at identifying pharmacological agents targeting the glutamatergic system and assess their efficacy.

Methods

In this systematic review, a PIO strategy was used to identify articles analyzing the efficacy of glutamatergic agents in bipolar disorder. Searches were conducted in the databases ClinicalTrials.gov, PubMed and Web of Science. Eligible studies included phase II/III randomized clinical trials and controlled trials involving patients diagnosed with bipolar disorder. Methodological quality was assessed using the Joanna Briggs Institute (JBI) appraisal tool. Data were extracted into comparative tables including key information such as pharmacological agent, dosage, inclusion/exclusion criteria, study duration and main findings.

Results

Thirteen articles were included in this study. Most trials were conducted in the United States of America (USA) (69%) and Taiwan (31%). USA studies primarily focused on ketamine, whereas Taiwanese studies investigated add-on memantine or dextromethorphan. Overall, glutamatergic modulators demonstrated promising effects in bipolar depression treatment, particularly ketamine, which was the most frequently studied agent. Ketamine stood out due to its rapid antidepressant effects.

Conclusions

Glutamatergic modulators, especially ketamine, represent a promising approach for treatment-resistant bipolar depression, mainly because of their rapid antidepressant effect and their ability to reduce symptoms such as anhedonia and suicidal ideation. However, further studies are required to confirm the long-term efficacy and safety of these pharmaceuticals.

Schlagwörter

bipolar disorderglutamatergic systemketaminememantinedextromethorphanbipolar depressiontreatment-resistant depressionrapid antidepressant effectsmood stabilizersanhedonia

Zitieren

APA

Coutinho, M., Moreira, F., & Santos, M. (2026). Targeting the Glutamatergic System in Bipolar Disorder - A Review of Pharmacological Approaches. Proceedings of Research and Practice in Allied and Environmental Health. https://doi.org/10.26537/prpaeh.v4i2.7367

Vancouver

Coutinho M, Moreira F, Santos M. Targeting the Glutamatergic System in Bipolar Disorder - A Review of Pharmacological Approaches. Proceedings of Research and Practice in Allied and Environmental Health. 2026. doi:10.26537/prpaeh.v4i2.7367

BibTeX
@article{Coutinho2026,
  author = {Coutinho, Margarida and Moreira, Fernando and Santos, Marlene},
  title = {Targeting the Glutamatergic System in Bipolar Disorder - A Review of Pharmacological Approaches},
  journal = {Proceedings of Research and Practice in Allied and Environmental Health},
  year = {2026},
  doi = {10.26537/prpaeh.v4i2.7367}
}
Kostenlos starten →